• Core testing revenue up 99% YoY, with 27 new clinic accounts signed since November 2025
• Australia Microbiome Explorer tests up 49% vs PCP, UK Microbiome Explorer tests up 232% vs PCP
• Preparing for major new product release in Q1 FY27 to expand addressable market

Microba Life Sciences Limited (ASX: MAP) has reported a strong Q3 FY26, with core testing revenue up 99% year-over-year and test volumes reaching an annualized run rate of over 23,000. In Australia, Microbiome Explorer delivered another record quarter, with 4,786 tests sold, up 49% versus the prior corresponding period. The company's strategy focused on contracts with healthcare clinics is delivering ahead of plan, with 27 new clinic accounts signed since November 2025. In the UK, adoption of Microbiome Explorer continues to grow, with 816 tests sold in the quarter, up 232% on the prior corresponding period. Microba is also preparing for a major new product release in early Q1 FY27, which is expected to open up the company's serviceable addressable market to more medical doctors. The company is in confidential negotiations regarding a significant corporate transaction that, if completed, would improve its financial position. Microba's therapeutics business has also seen positive developments, with a series of positive clinical trial readouts for the microbiome therapeutics sector from November 2025 to February 2026, which have strengthened the investment case and value of Microba's lead inflammatory bowel disease asset.

Microba is on track to meet regional break-even guidance by the end of FY26.

Microba remains intensively focused on growing its core testing products, on disciplined execution, and on securing the capital position of the company to continue to lead the development and capture of this major new diagnostic category.